Seven Axinn Attorneys Recognized by 2024 Empire State Counsel Program
October 8, 2025
Axinn is proud to announce that seven of our attorneys have been recognized by the 2024 Empire State Counsel Program, an initiative of the New York State Bar Association that honors lawyers who each contributed 50 hours or more of pro bono legal services in the past year.
This recognition reflects Axinn’s ongoing dedication to pro bono service and its commitment to ensuring access to justice for those in need.
The following Axinn attorneys were recognized for their contributions:
- Nicholas E.O. Gaglio
- Thomas G. Rohback
- Matthew L. Gorski
- Victoria J. Lu
- Tomasz W. Mielniczuk
- Kyle R. Sherwood
- Jason S. Wasserman
Like last year, the firm itself was also recognized by the New York State Bar Association and received a Firm Certificate in honor of its collective pro bono efforts.
About Axinn
Incisive. Inclusive. Invested. Inquisitive. We’re Axinn. Focusing on antitrust, intellectual property, and litigation, we make it our mission to understand your business so we can anticipate every move. Acting with precision and conviction, we protect and accelerate your business growth, always thinking ahead.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
Biosimilar Approval Pathway Changes Sponsors Need to Monitor
Media Mentions
Intellectual Property